NTLA Quote, Financials, Valuation and Earnings

Beam Therapeutics, Inc. has a net margin of -735.19% compared to Intellia Therapeutics, Inc.'s net margin of -1162.38%. Intellia Therapeutics, Inc.'s return on equity of -54.66% beat Beam Therapeutics, Inc.'s return on equity of -44.48%.

Intellia Therapeutics, Inc. has a consensus price target of $23.86, signalling upside risk potential of 71.63%. On the other hand Beam Therapeutics, Inc. has an analysts' consensus of $47.21 which suggests that it could grow by 61.2%. Given that Intellia Therapeutics, Inc. has higher upside potential than Beam Therapeutics, Inc., analysts believe Intellia Therapeutics, Inc. is more attractive than Beam Therapeutics, Inc..

Intellia Therapeutics, Inc. has a beta of 2.054, which suggesting that the stock is 105.378% more volatile than S&P 500. In comparison Beam Therapeutics, Inc. has a beta of 2.070, suggesting its more volatile than the S&P 500 by 107.038%.

Intellia Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Beam Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intellia Therapeutics, Inc. pays -- of its earnings as a dividend. Beam Therapeutics, Inc. pays out -- of its earnings as a dividend.

Intellia Therapeutics, Inc. quarterly revenues are $13.8M, which are larger than Beam Therapeutics, Inc. quarterly revenues of $9.7M. Intellia Therapeutics, Inc.'s net income of -$101.3M is higher than Beam Therapeutics, Inc.'s net income of -$112.7M. Notably, Intellia Therapeutics, Inc.'s price-to-earnings ratio is -- while Beam Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intellia Therapeutics, Inc. is 25.33x versus 49.35x for Beam Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pacific Biosciences of California, Inc. has a net margin of -735.19% compared to Intellia Therapeutics, Inc.'s net margin of -98.85%. Intellia Therapeutics, Inc.'s return on equity of -54.66% beat Pacific Biosciences of California, Inc.'s return on equity of -218.65%.

Intellia Therapeutics, Inc. has a consensus price target of $23.86, signalling upside risk potential of 71.63%. On the other hand Pacific Biosciences of California, Inc. has an analysts' consensus of $2.42 which suggests that it could grow by 1.97%. Given that Intellia Therapeutics, Inc. has higher upside potential than Pacific Biosciences of California, Inc., analysts believe Intellia Therapeutics, Inc. is more attractive than Pacific Biosciences of California, Inc..

Intellia Therapeutics, Inc. has a beta of 2.054, which suggesting that the stock is 105.378% more volatile than S&P 500. In comparison Pacific Biosciences of California, Inc. has a beta of 2.200, suggesting its more volatile than the S&P 500 by 120.046%.

Intellia Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pacific Biosciences of California, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intellia Therapeutics, Inc. pays -- of its earnings as a dividend. Pacific Biosciences of California, Inc. pays out -- of its earnings as a dividend.

Intellia Therapeutics, Inc. quarterly revenues are $13.8M, which are smaller than Pacific Biosciences of California, Inc. quarterly revenues of $38.4M. Intellia Therapeutics, Inc.'s net income of -$101.3M is lower than Pacific Biosciences of California, Inc.'s net income of -$38M. Notably, Intellia Therapeutics, Inc.'s price-to-earnings ratio is -- while Pacific Biosciences of California, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intellia Therapeutics, Inc. is 25.33x versus 4.62x for Pacific Biosciences of California, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Personalis, Inc. has a net margin of -735.19% compared to Intellia Therapeutics, Inc.'s net margin of -149.38%. Intellia Therapeutics, Inc.'s return on equity of -54.66% beat Personalis, Inc.'s return on equity of -39.33%.

Intellia Therapeutics, Inc. has a consensus price target of $23.86, signalling upside risk potential of 71.63%. On the other hand Personalis, Inc. has an analysts' consensus of $11.14 which suggests that it could grow by 11.76%. Given that Intellia Therapeutics, Inc. has higher upside potential than Personalis, Inc., analysts believe Intellia Therapeutics, Inc. is more attractive than Personalis, Inc..

Intellia Therapeutics, Inc. has a beta of 2.054, which suggesting that the stock is 105.378% more volatile than S&P 500. In comparison Personalis, Inc. has a beta of 1.960, suggesting its more volatile than the S&P 500 by 96.049%.

Intellia Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Personalis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intellia Therapeutics, Inc. pays -- of its earnings as a dividend. Personalis, Inc. pays out -- of its earnings as a dividend.

Intellia Therapeutics, Inc. quarterly revenues are $13.8M, which are smaller than Personalis, Inc. quarterly revenues of $14.5M. Intellia Therapeutics, Inc.'s net income of -$101.3M is lower than Personalis, Inc.'s net income of -$21.7M. Notably, Intellia Therapeutics, Inc.'s price-to-earnings ratio is -- while Personalis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intellia Therapeutics, Inc. is 25.33x versus 12.18x for Personalis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -735.19% compared to Intellia Therapeutics, Inc.'s net margin of 38.89%. Intellia Therapeutics, Inc.'s return on equity of -54.66% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Intellia Therapeutics, Inc. has a consensus price target of $23.86, signalling upside risk potential of 71.63%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $831.38 which suggests that it could grow by 10.93%. Given that Intellia Therapeutics, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Intellia Therapeutics, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Intellia Therapeutics, Inc. has a beta of 2.054, which suggesting that the stock is 105.378% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.390, suggesting its less volatile than the S&P 500 by 60.965%.

Intellia Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.47% to investors and pays a quarterly dividend of $0.88 per share. Intellia Therapeutics, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Intellia Therapeutics, Inc. quarterly revenues are $13.8M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Intellia Therapeutics, Inc.'s net income of -$101.3M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Intellia Therapeutics, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intellia Therapeutics, Inc. is 25.33x versus 5.80x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.